Board of Directors
Michel de Rosen
Chairman of the Board of Directors
More than 30 years of pharma and industry leadership experience. Board Chairman at DBV Technologies and Faurecia. Former CEO at Eutelsat and ViroPharma (now Shire), Rhône Poulenc Rorer and Rhône-Poulenc Santé (now Sanofi). Former General Manager at Pharmuka and Rhône-Poulenc Fibers and Polymers. Ex advisor to the Minister of Defense and Chief of Staff to the Minister of Industry and Telecommunications.
Managing Director of CB Lux.
More than 25 years in senior executive positions at major international business groups: Schlumberger, Schneider Electric, Valeo, Thomson. Former President and CEO of Converteam Group, acquired from Alstom, he developed and sold to General Electric after the value increased by 30. His fund ZAKA has especially invested in several biotechnology companies including Carmat and Cellectis of which he is Board member.
Founder and CEO of Epics Therapeutics SA, Chairman of the Board for both Syndesi Therapeutics SA and Bioxodes SA. Jean was earlier the CEO of Ogeda SA and has previously served in senior development roles at Sanofi. Significant experience in pre-clinical and clinical development.
Representing Tasly Hong-Kong Pharmaceutical Ltd
Co-founder and General Partner of Truffle Capital. Leading investor in biotech/medtech in France and US. Founder and Chairman of Deinove and Abivax, co-founder and Board member of Carbios, Carmat, Biokinésis, Pharnext, Vexim. Board member of Myopowers, Kephalios, Symetis, Theraclion, Theradiag, Altimmune, Innate Pharma. Founder of SangStat (Genzyme) and Conjuchem. Former Chairman of France Biotech, conceived the Young Innovative Entreprise Status (JEI), ex-Vice Chairman of Europabio.
Chief Strategy and Business Development Officer of Mallinckrodt Pharmaceuticals and serves as a Board member of Shuttle Pharmaceuticals. Josh was earlier head of the oncology franchise at Astellas and held senior roles at Takeda. Josh has successfully led over $16 billion in M&A transactions.
David H. Solomon
More than 30 years of experience within the life sciences industry. Former CEO of Silence Therapeutics, Akari Therapeutics, Bionor Parma, Zealand Pharma. Former managing partner at Sund Capital. Previously headed healthcare investments at Carrot Capital Healthcare Ventures. Former Board member of TxCell (acquired by Sangamo Therapeutics), Onxeo and Promosome. Now Chairman of the Board for Advicenne Pharma and Rexgenero.
Professor of Neurology and Neurological Sciences, Pediatrics and Genetics at Stanford University. Larry is the GA Zimmermann Chair of Neurological Sciences, Neurology and Pediatrics.
Chief Development Officer at Ixaltis SA, Elisabeth serves as a Board member of Galapagos NV and Swedish Orphan Biovitrum (SOBI), among others. Elisabeth has served in senior development roles at Serono, Bristol-Meyers Squibb and Johnson&Johnson.